Fig. 5

The effect of TP53INP2 overexpression on proliferation and autophagy of GC cells. A The expression of TP53INP2 in different types of carcinomas (http://ualcan.path.uab.edu). BLCA: bladder urothelial carcinoma; BRCA: breast invasive carcinoma; CESC: cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL: cholangiocarcinoma; COAD: colon adenocarcinoma; ESCA: esophageal carcinoma; GBM: glioblastoma multiforme; HNSC: head and neck squamous cell carcinoma; KICH: kidney chromophobe; KIRC: kidney renal clear cell carcinoma; KIRP: kidney renal papillary cell carcinoma; LIHC: liver hepatocellular carcinoma; LUAD: lung adenocarcinoma; LUSC: lung squamous cell carcinoma; PAAD: pancreatic adenocarcinoma; PRAD: prostate adenocarcinoma; PCPG: prostate adenocarcinoma; READ: rectum adenocarcinoma; SARC: sarcoma; SKCM: skin cutaneous melanoma; THCA: thyroid carcinoma; THYM: thymoma; STAD: stomach adenocarcinoma; UCEC: uterine corpus endometrial carcinoma. B The relative expression of TP53INP2 in GC and adjacent tissues from TCGA database (normal mucosa = 34, tumor tissue = 415). C IHC staining reveals TP53INP2 levels in GC tissue and para-carcinoma tissue. D Overexpression of TP53INP2 in AGS and NCI-N87 cells was evidenced by qRT-PCR. E Growth curves representing cell viability were inhibited by TP53INP2 in both AGS and NCI-N87 cells. F Overexpression of TP53INP2 suppressed colony formation in both AGS and NCI-N87 cells. G Western blotting analysis of TP53INP2, p62/SQSTM1 and LC3 in TP53INP2 overexpressed and control groups. H After stably transfected with tandem-labeled mRFP-GFP-LC3, representative images of mRFP-GFP-LC3 vector were shown by immunofluorescent detection. Each experiment was performed in triplicate and repeated at least three times. Data were represented as mean ± SD. **p < 0.01, ***p < 0.001, ****p < 0.0001